Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Genovate Biotechnology Co., Ltd. (4130:TWSE), powered by AI.
Genovate Biotechnology Co., Ltd. is currently trading at $34.05. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Genovate Biotechnology Co., Ltd. on Alpha Lenz.
View Genovate Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.
“Genovate Biotechnology Co., Ltd.'s ROE is 0.8%. Explore profitability and growth together.”
Ask for details →Genovate Biotechnology Co., Ltd. is a healthcare company specializing in the research, development, manufacturing, and sale of pharmaceutical products. Its primary function is to provide a broad range of specialty drugs and active pharmaceutical ingredients targeting diseases caused by viruses and bacteria, with a portfolio that includes antimicrobial, anticancer, cardiovascular, alimentary tract, metabolic, dermatologic, musculoskeletal, nervous system, respiratory, and urinary system drugs. The company also develops controlled-release dosage forms and is active in the cosmetics segment as well as healthcare foods. Founded in 1982 and headquartered in Hsinchu, Taiwan, Genovate Biotechnology plays a significant role within the Taiwanese pharmaceutical and biotechnology sector, supporting both the domestic healthcare market and the ongoing development of new therapeutic products. By integrating clinical experimental services and technology exports into its business, the company enhances its market relevance and helps address a range of prevalent medical needs across multiple therapeutic areas.
“Genovate Biotechnology Co., Ltd.'s ROE is 0.8%. Explore profitability and growth together.”
Ask for details →